As poor adherence to HIV treatment can result in drug resistance and inadequate treatment of HIV, it’s important to identify adherence interventions that are inexpensive and proven to be effective in resource-limited settings. The study complements a recently available study on cell-phone strategies to boost adherence to HIV treatment released in Lancet 2010, which Chung contributed as a co-author also. Related StoriesNew study discovers high prevalence of HIV among pregnant refugee women in OntarioPitt Public Health launches study to promote health among maturing gay and bisexual guys with HIVNew computer model predicts levels of HIV care engagementChung helped the Coptic Medical center in Kenya create the Hope Clinic, a free HIV treatment and care clinic.MabThera may be the first and only selective B-cell therapy for RA, providing a fundamentally different remedy approach by targeting B cells, one of the key players in the pathogenesis of RA. Actemra is usually Roche’s second novel medication and is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of IL-6, a protein that plays a significant function in the RA swelling process. Additional projects creating a rich pipeline include substances in Phase I, II and III scientific trials. Notably, ocrelizumab, a humanised anti-CD20 antibody, offers entered phase III development for RA. About Roche Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare organizations in the areas of pharmaceuticals and diagnostics.